- Home
- CFBK vs SPRO Comparison
CFBK vs SPRO Comparison
Compare CFBK & SPRO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CFBK
- SPRO
- Stock Information
- Founded
- CFBK 1892
- SPRO 2013
- Country
- CFBK United States
- SPRO United States
- Employees
- CFBK N/A
- SPRO N/A
- Industry
- CFBK Major Banks
- SPRO Biotechnology: Pharmaceutical Preparations
- Sector
- CFBK Finance
- SPRO Health Care
- Exchange
- CFBK Nasdaq
- SPRO Nasdaq
- Market Cap
- CFBK 154.9M
- SPRO 162.1M
- IPO Year
- CFBK 1998
- SPRO 2017
- Fundamental
- Price
- CFBK $23.81
- SPRO $2.33
- Analyst Decision
- CFBK Buy
- SPRO Buy
- Analyst Count
- CFBK 1
- SPRO 4
- Target Price
- CFBK $29.00
- SPRO $5.00
- AVG Volume (30 Days)
- CFBK 43.9K
- SPRO 890.8K
- Earning Date
- CFBK 08-04-2025
- SPRO 08-04-2025
- Dividend Yield
- CFBK 1.34%
- SPRO N/A
- EPS Growth
- CFBK N/A
- SPRO N/A
- EPS
- CFBK 2.28
- SPRO N/A
- Revenue
- CFBK $47,663,000.00
- SPRO $44,584,000.00
- Revenue This Year
- CFBK $35.39
- SPRO N/A
- Revenue Next Year
- CFBK $10.11
- SPRO N/A
- P/E Ratio
- CFBK $10.43
- SPRO N/A
- Revenue Growth
- CFBK 1.22
- SPRO N/A
- 52 Week Low
- CFBK $19.23
- SPRO $0.51
- 52 Week High
- CFBK $31.17
- SPRO $3.22
- Technical
- Relative Strength Index (RSI)
- CFBK 47.44
- SPRO 38.82
- Support Level
- CFBK $23.76
- SPRO $2.30
- Resistance Level
- CFBK $24.17
- SPRO $2.45
- Average True Range (ATR)
- CFBK 0.36
- SPRO 0.14
- MACD
- CFBK -0.03
- SPRO -0.08
- Stochastic Oscillator
- CFBK 30.30
- SPRO 3.26
About CFBK CF Bankshares Inc.
CF Bankshares Inc is engaged in the provision of a variety of financial services. It provides personalized business banking products and services, including commercial loans and leases, commercial and residential real estate loans, equipment leasing, SBA loans and treasury management depository services. The revenues are derived principally from the interest and fees on loans originated and noninterest income generated on the sale of loans.
About SPRO Spero Therapeutics Inc.
Spero Therapeutics Inc is a clinical-stage biopharmaceutical firm. It focuses on identifying, developing, and commercializing novel treatments for MDR (Multi-drug-resistant) bacterial infections and rare diseases. The company's product candidate, tebipenem pivoxil hydrobromide or tebipenem HBr, is designed to be an oral carbapenem-class antibiotic for use in adults to treat MDR Gram-negative infections. It is also developing SPR720, a novel oral antibiotic designed for the treatment of a rare, orphan disease caused by pulmonary non-tuberculous mycobacterial infections, or NTM disease. Besides, it is also focused on SPR206, a next-generation polymyxin investigational product candidate being developed as an IV-administered medicine to treat MDR Gram-negative infections in the hospital.